DRTS - Alpha Tau Medical Ltd Company Long-Term Liabilities

This long-term liability chart for Alpha Tau Medical Ltd. (DRTS) illustrates the financial profile of a company that integrates ESG principles into the development of alpha-therapy systems and strictly adheres to bioethical standards. The current figure is 0.01. The company has outsourced the production of mechanical components, while key radiation developments remain in-house. The business specializes in innovative targeted irradiation, integrating its proprietary solutions into clinical protocols.

alphatau.com (DRTS) Company Long-Term Debt: for the period 04/28/2023 - 10/30/2026

Alpha Tau (DRTS) - metric breakdowns and financial figures

- stock value and consensus price forecast:

Market Chart alphatau.com|DRTS - Analyst Consensus Forecast

- market capitalization statistics:

Market Valuation Alpha Tau Medical|DRTS - Enterprise Value

- shareholders' equity book value data:

Net Asset Value per Share Alpha Tau Medical|DRTS - Company Book Value|Market Value to Book Value Ratio alphatau.com|DRTS - Aggregate Company Assets

- business debt structure and liquidity details:

- earnings and market multiples details:

DRTS - Net Income

Analysis of all company metrics:alphatau.com - DRTS

Long-term debt records the total volume of borrowed funds with maturities exceeding twelve months, determining the issuer's financial stability. The dynamics of a company's long-term debt allow for a real-time assessment of debt service costs under tight monetary policy conditions. This metric measures default risk through the ratio of credit load to equity. For Alpha Tau Medical Ltd. (DRTS), such a borrowing structure remains stable due to the non-cyclical nature of cancer therapy development.

Who Alpha Tau Medical Ltd. competes with

Long-Term Debt Volume novocure.com (NVCR)|Fortress Biotech - Company Long-Term Debts|Acrivon Therapeutics Inc (ACRV) - Company Long-Term Liabilities|ALLR: Company Long-Term Debts